“…At present, there are several commercial assays for bladder cancer diagnosis based on immunoassays, but they have high variability of sensitivity and specificity. In addition, in most of them the false-positive rate is quite high, they require tedious/laborious assay procedures, are time consuming, expensive and need specialized personnel [9,10]. To this aim, the development of portable, low cost, multiplexed and easy to use devices that, within minutes, can detect cancer biomarkers directly from biofluids is instrumental.…”